Editas Medicine (EDIT) Share-based Compensation (2015 - 2025)

Editas Medicine (EDIT) has reported Share-based Compensation for 11 consecutive years, with $2.2 million the latest figure, recorded in Q3 2025.

• In Q3 2025, Share-based Compensation fell 53.6% year-over-year to $2.2 million; the TTM figure through Sep 2025 stood at $11.9 million (down 47.71% YoY), while the FY2024 annual figure was $21.4 million, up 8.18% from the prior year.
• Share-based Compensation retreated to $2.2 million in Q3 2025 per EDIT's latest filing, from $2.7 million in the prior quarter.
• Across five years, Share-based Compensation topped out at $37.0 million in Q3 2022 and bottomed at $526000.0 in Q2 2021.
• Historically, Share-based Compensation has averaged $7.4 million across 5 years, with a median of $5.2 million in 2023.
• Annual changes were most pronounced in 2022 — Share-based Compensation soared 1158.17% — and 2023, when it plunged 87.21%.
• Editas Medicine's Share-based Compensation stood at $7.7 million in 2021, then retreated by 29.95% to $5.4 million in 2022, then declined by 0.35% to $5.3 million in 2023, then dropped by 24.79% to $4.0 million in 2024, then sank by 44.58% to $2.2 million in 2025.
• Business Quant data shows EDIT's Share-based Compensation at $2.2 million in Q3 2025, $2.7 million in Q2 2025, and $3.0 million in Q1 2025.